TickerFacts.

bioAffinity Technologies, Inc. (BIAF): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$1.38M
Year ended 2025-12-31
$1.42M
Trailing 12 months to 2026-06-30
+0.1%
3-year compound annual growth
$1.47M2021-12-31: $1.01M2022-12-31: $1.38M2023-12-31: $1.47M2024-12-31: $1.46M2025-12-31: $1.38M$1.38M
2021-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$1.38M-5.3%2026-03-16, From 2025-01-01
2024-12-31$1.46M-0.5%2026-03-16, From 2024-01-01
2023-12-31$1.47M+6.5%2025-03-31, From 2023-01-01
2022-12-31$1.38Mn/c2024-04-01, From 2022-01-01
2021-12-31$1.01Mn/a2023-03-31, From 2021-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
bioAffinity Technologies, Inc. (BIAF)2025-12-31$1.38M-5.3%
Absci Corp (ABSI)2025-12-31$81.42M+27.5%
Foxo Technologies Inc. (FOXO)2025-12-31$182.5K-41.6%
OmniAb, Inc. (OABI)2025-12-31$47.75M-13.3%
iSpecimen Inc. (ISPC)2024-12-31$1.49M-7.8%
OneMedNet Corp (ONMD)2025-12-31$1.51M+3.3%
MaxCyte, Inc. (MXCT)2025-12-31$20.82M-6.3%
Incyte Corp (INCY)2025-12-31$2.05B-21.4%

Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗